- Home
- AMGN vs GILD Comparison
AMGN vs GILD Comparison
Compare AMGN & GILD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- GILD
- Stock Information
- Founded
- AMGN 1980
- GILD 1987
- Country
- AMGN United States
- GILD United States
- Employees
- AMGN N/A
- GILD N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- AMGN Health Care
- GILD Health Care
- Exchange
- AMGN Nasdaq
- GILD Nasdaq
- Market Cap
- AMGN 150.8B
- GILD 145.4B
- IPO Year
- AMGN N/A
- GILD 1992
- Fundamental
- Price
- AMGN $295.58
- GILD $123.11
- Analyst Decision
- AMGN Hold
- GILD Buy
- Analyst Count
- AMGN 15
- GILD 22
- Target Price
- AMGN $313.57
- GILD $120.90
- AVG Volume (30 Days)
- AMGN 2.1M
- GILD 6.7M
- Earning Date
- AMGN 11-04-2025
- GILD 10-30-2025
- Dividend Yield
- AMGN 3.21%
- GILD 2.57%
- EPS Growth
- AMGN 110.88
- GILD 6514.05
- EPS
- AMGN 12.23
- GILD 6.42
- Revenue
- AMGN $34,917,000,000.00
- GILD $29,087,000,000.00
- Revenue This Year
- AMGN $8.82
- GILD $3.05
- Revenue Next Year
- AMGN $1.84
- GILD $3.29
- P/E Ratio
- AMGN $24.26
- GILD $19.15
- Revenue Growth
- AMGN 12.88
- GILD 2.79
- 52 Week Low
- AMGN $253.30
- GILD $86.08
- 52 Week High
- AMGN $335.88
- GILD $124.61
- Technical
- Relative Strength Index (RSI)
- AMGN 54.10
- GILD 63.90
- Support Level
- AMGN $288.26
- GILD $114.02
- Resistance Level
- AMGN $301.00
- GILD $121.58
- Average True Range (ATR)
- AMGN 5.96
- GILD 3.33
- MACD
- AMGN -0.33
- GILD 0.01
- Stochastic Oscillator
- AMGN 46.95
- GILD 85.84
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).